Santhera Launches US Expanded Access Program with Idebenone for Patients with Duchenne …

Heart Disease

"I commend Santhera for developing the BreatheDMD program, allowing eligible patients to access idebenone, an investigational medicine that has shown the ability to slow respiratory function decline in a completed Phase III (DELOS) trial. We desperately need alternative treatment options for patients …
Go to Source

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave